Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $10.14 Average Target Price from Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have received a consensus rating of “Hold” from the nine ratings firms that are presently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $10.14.

Several analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $5.00 target price on shares of Neumora Therapeutics in a report on Tuesday, March 4th. William Blair cut shares of Neumora Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, March 10th. Stifel Nicolaus cut shares of Neumora Therapeutics from a “buy” rating to a “hold” rating and cut their target price for the stock from $6.00 to $2.00 in a research report on Friday, March 7th. Royal Bank of Canada restated a “sector perform” rating and set a $4.00 target price on shares of Neumora Therapeutics in a research report on Tuesday, March 4th. Finally, HC Wainwright cut their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th.

Neumora Therapeutics Stock Performance

Shares of Neumora Therapeutics stock opened at $1.16 on Tuesday. Neumora Therapeutics has a 1 year low of $1.13 and a 1 year high of $17.19. The company has a market capitalization of $187.90 million, a P/E ratio of -0.62 and a beta of 2.59. The company’s fifty day moving average is $1.75 and its two-hundred day moving average is $7.99.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.09. As a group, equities analysts expect that Neumora Therapeutics will post -1.61 earnings per share for the current year.

Institutional Investors Weigh In On Neumora Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in Neumora Therapeutics by 4.5% during the fourth quarter. Vanguard Group Inc. now owns 4,572,308 shares of the company’s stock worth $48,466,000 after buying an additional 195,142 shares during the period. Capital International Investors boosted its stake in shares of Neumora Therapeutics by 692.1% in the fourth quarter. Capital International Investors now owns 3,700,359 shares of the company’s stock valued at $39,224,000 after purchasing an additional 3,233,179 shares during the period. Geode Capital Management LLC boosted its stake in shares of Neumora Therapeutics by 54.0% in the third quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock valued at $26,159,000 after purchasing an additional 694,385 shares during the period. State Street Corp boosted its stake in shares of Neumora Therapeutics by 65.3% in the third quarter. State Street Corp now owns 1,790,707 shares of the company’s stock valued at $23,655,000 after purchasing an additional 707,409 shares during the period. Finally, Rock Springs Capital Management LP boosted its stake in shares of Neumora Therapeutics by 15.3% in the fourth quarter. Rock Springs Capital Management LP now owns 955,106 shares of the company’s stock valued at $10,124,000 after purchasing an additional 127,005 shares during the period. 47.65% of the stock is currently owned by hedge funds and other institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.